Welcome to our dedicated page for Kalaris Therapeutics news (Ticker: KLRS), a resource for investors and traders seeking the latest updates and insights on Kalaris Therapeutics stock.
Kalaris Therapeutics develops clinical-stage biopharmaceutical treatments for retinal diseases, with company updates centered on TH103, its investigational biologic for neovascular age-related macular degeneration and other sight-threatening retinal conditions.
Recurring news includes Phase 1 clinical data, safety and pharmacokinetic presentations, manufacturing and clinical-supply arrangements, financial results and cash runway commentary, capital actions, healthcare conference presentations, and leadership changes as the company advances its retinal-disease program.
Kalaris Therapeutics (Nasdaq: KLRS) appointed Liisa Bayko, MBA, as Chief Financial Officer, adding a strategic finance leader with more than 20 years of biotechnology experience to its leadership team. The company highlighted her background in assessing and valuing biotech companies, investor engagement, and capital markets.
Bayko previously served as Managing Director and Senior Biotechnology Analyst at Evercore ISI and held senior equity research roles at several firms. Her appointment comes as Kalaris advances enrollment in its Phase 1b/2 clinical trial of TH103 for treatment-naïve neovascular age-related macular degeneration (nAMD) and continues developing therapies for prevalent retinal diseases.
Kalaris Therapeutics (Nasdaq: KLRS) reported additional positive Phase 1a single-ascending-dose data for TH103 in neovascular age-related macular degeneration. The expanded dataset now covers 17 treatment-naive and 3 treatment-experienced patients, all with six months of follow-up.
According to Kalaris, treatment-naive patients showed continued structural and functional improvements, with pharmacokinetics indicating 27- to 53-fold lower plasma Cmax versus current leading anti-VEGF agents on a molar basis, suggesting higher intraocular retention. After a single TH103 injection, 41% of treatment-naive patients were retreated at ≥4 months, 35% at ≥5 months, and 29% required no additional anti-VEGF therapy over six months. In treatment-experienced patients, retreatment intervals extended by an average of 2 months. No intraocular inflammation occurred in six patients at 2.5 mg using adjusted manufacturing; one 5 mg patient had transient IOI that resolved. Enrollment continues in a Phase 1b/2 multiple-ascending-dose trial, with initial data expected in 1H 2027.
Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharmaceutical company focused on retinal diseases, appointed Laurie Keating to its Board of Directors, effective August 1, 2026. Morana Jovan-Embiricos will step down from the Board in conjunction with this change.
Keating brings broad strategic, operational, and legal experience from senior roles and board positions across multiple biotechnology companies, including Alnylam Pharmaceuticals, Millennium Pharmaceuticals, PepGen, and Immuneering. Kalaris’ leadership highlights her expected contributions as the company advances its retinal disease programs.
Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for TH103, a dual-targeting VEGF/HSPG biologic for neovascular age-related macular degeneration, at the ASRS 2026 Annual Meeting on July 17, 2026, in Montréal.
The company reports its Phase 1b/2 multiple ascending dose trial of TH103 in neovascular AMD is actively enrolling and dosing patients, with initial data expected in 1H 2027 to guide potential future Phase 3 dose selection.
Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharma focused on retinal diseases, will present Phase 1a single ascending dose data for lead asset TH103 in treatment-naïve neovascular age-related macular degeneration at Clinical Trials at the Summit 2026 in Las Vegas.
The session occurs June 13, 2026, 07:09 am PDT, in the Azure Ballroom.
Kalaris (Nasdaq: KLRS) reported first quarter 2026 results and clinical progress for retinal drug TH103. Patient screening is underway in the Phase 1b/2 nAMD study, with preliminary data expected in 1H 2027 and Phase 3 trials targeted to start by year-end 2027.
Kalaris reported $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026, expected to fund operations into Q4 2027. Q1 2026 R&D expenses were $7.6 million, G&A expenses were $4.3 million, and net loss was $10.9 million.
Kalaris (Nasdaq: KLRS) reported full year 2025 results and business updates on March 17, 2026. Key developments include positive Phase 1a nAMD data showing mean 10‑letter BCVA improvement, mean 129μm CST reduction, ~95% intraretinal fluid reduction and 27–51x lower plasma Cmax versus leading anti‑VEGF agents.
Financials: completed a $50.0M private placement, held $118.0M in cash and marketable securities at 12/31/2025, and expects that funding into Q4 2027; 2025 net loss was $43.4M.
Kalaris (NASDAQ: KLRS) will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego.
The Feb 26 presentation by Dean Eliott, MD will cover safety, tolerability, pharmacokinetics and early efficacy after intravitreal dosing in treatment‑naive neovascular AMD.
Kalaris Therapeutics (NASDAQ: KLRS) entered a securities purchase agreement for an oversubscribed private placement to raise approximately $50.0 million gross, expected to close on or about December 19, 2025.
The financing consists of 4,200,000 common shares at $10.00 per share and 800,000 pre-funded warrants at $9.9999 each (exercise price $0.0001), with resale registration rights to be filed with the SEC. Morgan Stanley, Leerink Partners, and William Blair act as placement agents.
Based on current plans, management expects the net proceeds plus existing cash will fund operations into the third quarter of 2027, and proceeds will advance clinical development of TH103 for neovascular AMD and for general corporate purposes.
Kalaris Therapeutics (NASDAQ: KLRS) reported positive initial Phase 1a single ascending dose data for TH103 in treatment‑naïve neovascular AMD (N=13) with three dose levels (0.5 mg, 1.5 mg, 2.5 mg) and 6 months follow‑up. Key outcomes at Month 1 included a mean +10‑letter BCVA, −129 μm central subfield thickness (CST), and ~95% reduction in central intraretinal fluid. Pharmacokinetics showed dose‑adjusted plasma Cmax 27–51‑fold lower versus current leading agents. After one injection, 31% of patients required no additional anti‑VEGF treatment through 6 months. Two transient cases of intraocular inflammation at 2.5 mg were attributed to host cell protein; manufacturing was updated and no new IOI cases were seen with purified material. Kalaris is accelerating its Phase 1b/2 multi‑ascending dose study and expects preliminary data in 2H 2026. Conference call/webcast held today at 4:30 PM ET.